The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Full approval will depend on verification of clinical benefit in a confirmatory trial
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Subscribe To Our Newsletter & Stay Updated
